{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:33:16Z","timestamp":1787027596369,"version":"build-2736575974"},"reference-count":87,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Lung transplant recipients are at higher risk to develop infectious diseases due to multi-drug resistant pathogens, which often chronically colonize the respiratory tract before transplantation. The emergence of these difficult-to-treat infections is a therapeutic challenge, and it may represent a contraindication to lung transplantation. New antibiotic options are currently available, but data on their efficacy and safety in the transplant population are limited, and clinical evidence for choosing the most appropriate antibiotic therapy is often lacking. In this review, we provide a summary of the best evidence available in terms of choice of antibiotic and duration of therapy for MDR\/XDR P. aeruginosa, Burkholderia cepacia complex, Mycobacterium abscessus complex and Nocardia spp. infections in lung transplant candidates and recipients.<\/jats:p>","DOI":"10.3390\/antibiotics11050612","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T08:26:35Z","timestamp":1651566395000},"page":"612","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach"],"prefix":"10.3390","volume":"11","author":[{"given":"Lorena","family":"van den Bogaart","sequence":"first","affiliation":[{"name":"Infectious Diseases Service and Transplantation Center, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Manuel","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service and Transplantation Center, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.21037\/jtd-2021-12","article-title":"Bacterial infections in lung transplantation","volume":"13","author":"McCort","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/14017431.2020.1726444","article-title":"Incidence and impact of chronic lung allograft dysfunction after lung transplantation\u2014Single-center 14-year experience","volume":"54","author":"Nykanen","year":"2020","journal-title":"Scand. Cardiovasc. J."},{"key":"ref_3","unstructured":"(2022, March 28). Antimicrobial resistance surveillance in Europe. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/ECDC-WHO-AMR-report.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trre.2017.07.001","article-title":"Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"32","author":"Aguado","year":"2018","journal-title":"Transplant. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/tid.12356","article-title":"Nosocomial bloodstream infections in a nationwide study: Comparison between solid organ transplant patients and the general population","volume":"17","author":"Camargo","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-3062.2009.00380.x","article-title":"Pseudomonas aeruginosa bacteremia over a 10-year period: Multidrug resistance and outcomes in transplant recipients","volume":"11","author":"Johnson","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/TP.0000000000000366","article-title":"Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients","volume":"99","author":"Bodro","year":"2015","journal-title":"Transplantation"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Holm, A.E., Schultz, H.H.L., Johansen, H.K., Pressler, T., Lund, T.K., Iversen, M., and Perch, M. (2021). Bacterial Re-Colonization Occurs Early after Lung Transplantation in Cystic Fibrosis Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061275"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: An approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e00031-19","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.rmed.2008.11.015","article-title":"Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis","volume":"103","author":"Gottlieb","year":"2009","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/TP.0b013e318286e076","article-title":"Bronchiolitis obliterans syndrome and restrictive allograft syndrome: Do risk factors differ?","volume":"95","author":"Verleden","year":"2013","journal-title":"Transplantation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1183\/09031936.00128607","article-title":"Pseudomonal airway colonisation: Risk factor for bronchiolitis obliterans syndrome after lung transplantation?","volume":"31","author":"Vos","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e31816651de","article-title":"Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome","volume":"85","author":"Botha","year":"2008","journal-title":"Transplantation"},{"key":"ref_17","first-page":"CD001021","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"3","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Smyth","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Varannai, O., Gede, N., Juhasz, M.F., Szakacs, Z., Dembrovszky, F., Nemeth, D., Hegyi, P., and Parniczky, A. (2021). Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis-A Network Meta-Analysis. Antibiotics, 10.","DOI":"10.3390\/antibiotics10080936"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti","year":"2012","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2001720","DOI":"10.1183\/13993003.01720-2020","article-title":"Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: A retrospective cohort analysis","volume":"56","author":"Sacreas","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hirama, T., Tomiyama, F., Notsuda, H., Watanabe, T., Watanabe, Y., Oishi, H., and Okada, Y. (2021). Outcome and prognostic factors after lung transplantation for bronchiectasis other than cystic fibrosis. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01634-z"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e12688","DOI":"10.1111\/tid.12688","article-title":"Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation","volume":"19","author":"Moore","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.00201012","article-title":"Inhaled colistin following lung transplantation in colonised cystic fibrosis patients","volume":"42","author":"Suhling","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e13594","DOI":"10.1111\/ctr.13594","article-title":"Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Pouch","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs. Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"ofab089","DOI":"10.1093\/ofid\/ofab089","article-title":"A Multicenter Evaluation of Ceftolozane\/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections","volume":"8","author":"Hart","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Young, K., Painter, R.E., Raghoobar, S.L., Hairston, N.N., Racine, F., Wisniewski, D., Balibar, C.J., Villafania, A., Zhang, R., and Sahm, D.F. (2019). In Vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol., 19.","DOI":"10.1186\/s12866-019-1522-7"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Gatti, M., Viaggi, B., Rossolini, G.M., Pea, F., and Viale, P. (2021). An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010033"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy against Multidrug-Resistant Pseudomonas aeruginosa","volume":"220","author":"Zeiser","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Carugati, M., Piazza, A., Peri, A.M., Cariani, L., Brilli, M., Girelli, D., Di Carlo, D., Gramegna, A., Pappalettera, M., and Comandatore, F. (2020). Fatal respiratory infection due to ST308 VIM-1-producing Pseudomonas aeruginosa in a lung transplant recipient: Case report and review of the literature. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05338-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.01953-12","article-title":"FIM-1, a new acquired metallo-beta-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy","volume":"57","author":"Pollini","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"115227","DOI":"10.1016\/j.diagmicrobio.2020.115227","article-title":"Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-beta-lactamase-producing Pseudomonas aeruginosa","volume":"99","author":"Lee","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Monsel, A., Roberts, J.A., Pontikis, K., Mimoz, O., Rello, J., Qu, J., Rouby, J.J., and on behalf of the European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP) (2021). Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives. Microorganisms, 9.","DOI":"10.3390\/microorganisms9061154"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CCM.0000000000000771","article-title":"The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: A systematic review and metaanalysis","volume":"43","author":"Valachis","year":"2015","journal-title":"Crit. Care Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijantimicag.2015.09.011","article-title":"Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: A systematic review and meta-analysis","volume":"46","author":"Liu","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2018.02.002","article-title":"Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis","volume":"76","author":"Vardakas","year":"2018","journal-title":"J. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/01.mcp.0000181475.85187.ed","article-title":"Update on the Burkholderia cepacia complex","volume":"11","author":"Lipuma","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.healun.2010.06.007","article-title":"Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: A single-center experience","volume":"29","author":"Meachery","year":"2010","journal-title":"J. Heart Lung Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1164\/rccm.200712-1834OC","article-title":"Impact of Burkholderia infection on lung transplantation in cystic fibrosis","volume":"178","author":"Murray","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(01)06808-8","article-title":"Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis","volume":"358","author":"McDowell","year":"2001","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1164\/ajrccm.164.11.2107022","article-title":"Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type","volume":"164","author":"Aris","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e13236","DOI":"10.1111\/ctr.13236","article-title":"Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia dolosa (genomovar VI)","volume":"32","author":"Wang","year":"2018","journal-title":"Clin. Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1055\/s-0041-1728797","article-title":"The Impact of Resistant Bacterial Pathogens including Pseudomonas aeruginosa and Burkholderia on Lung Transplant Outcomes","volume":"42","author":"Mitchell","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2018.10.013","article-title":"Pre-transplant factors associated with mortality after lung transplantation in cystic fibrosis: A systematic review and meta-analysis","volume":"18","author":"Koutsokera","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/acsinfecdis.7b00020","article-title":"Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients","volume":"3","author":"Becka","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ajt.12096","article-title":"Multidrug-resistant gram-negative bacteria infections in solid organ transplantation","volume":"13","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13082","DOI":"10.1111\/tid.13082","article-title":"Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis","volume":"21","author":"Dacco","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/jac\/dky136","article-title":"Successful treatment of resistant Burkholderia multivorans infection in a patient with cystic fibrosis using ceftazidime\/avibactam plus aztreonam","volume":"73","author":"Barlow","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e02213-17","DOI":"10.1128\/AAC.02213-17","article-title":"Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam","volume":"62","author":"Tamma","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/JCM.00181-19","article-title":"\u201cSwitching Partners\u201d: Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0133221","DOI":"10.1128\/AAC.01332-21","article-title":"Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli","volume":"65","author":"Becka","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e02315-18","DOI":"10.1128\/AAC.02315-18","article-title":"Resurrecting Old beta-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant Burkholderia Species Isolates from the United States","volume":"6","author":"Zeiser","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ejcts\/ezx359","article-title":"Use of taurolidine in lung transplantation for cystic fibrosis and impact on bacterial colonization","volume":"53","author":"Zeriouh","year":"2018","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/08942680252908575","article-title":"A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia","volume":"15","author":"Ledson","year":"2002","journal-title":"J. Aerosol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01257-09","article-title":"Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france","volume":"47","author":"Roux","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0038-1651494","article-title":"Treatment of Mycobacterium abscessus Complex","volume":"39","author":"Strnad","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1128\/JCM.01688-08","article-title":"Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii","volume":"47","author":"Zelazny","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JCM.01175-12","article-title":"Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases","volume":"50","author":"Harada","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cid\/ciw723","article-title":"Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense","volume":"64","author":"Park","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e13274","DOI":"10.1111\/tid.13274","article-title":"Outcome according to subspecies following lung transplantation in cystic fibrosis pediatric patients infected with Mycobacterium abscessus","volume":"22","author":"Kavaliunaite","year":"2020","journal-title":"Transpl. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.transproceed.2012.02.035","article-title":"Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: A retrospective analysis in a Danish patient population","volume":"45","author":"Qvist","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/ctr.12140","article-title":"Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections","volume":"27","author":"Lobo","year":"2013","journal-title":"Clin. Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Tissot, A., Thomas, M.F., Corris, P.A., and Brodlie, M. (2018). NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: A worldwide survey of clinical practice. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0635-3"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.transproceed.2019.02.028","article-title":"Outcomes in Lung Transplant Recipients With Mycobacterium abscessus Infection: A 15-Year Experience From a Large Tertiary Care Center","volume":"51","author":"Hamad","year":"2019","journal-title":"Transplant. Proc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In Vitro Activity of the New beta-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with beta-Lactams against Mycobacterium abscessus Complex Clinical Isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"ofab093","DOI":"10.1093\/ofid\/ofab093","article-title":"Tedizolid vs. Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients","volume":"8","author":"Poon","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"ofab002","DOI":"10.1093\/ofid\/ofab002","article-title":"Preliminary, Real-world, Multicenter Experience with Omadacycline for Mycobacterium abscessus Infections","volume":"8","author":"Morrisette","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease: A retrospective analysis of 65 patients","volume":"180","author":"Jeon","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Uyttebroek, S., Chen, B., Onsea, J., Ruythooren, F., Debaveye, Y., Devolder, D., Spriet, I., Depypere, M., Wagemans, J., and Lavigne, R. (2022). Safety and efficacy of phage therapy in difficult-to-treat infections: A systematic review. Lancet. Infect. Dis., Online ahead of print.","DOI":"10.1016\/S1473-3099(21)00612-5"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/cid\/ciw241","article-title":"Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study","volume":"63","author":"Coussement","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/QCO.0000000000000782","article-title":"Management dilemmas in Nocardia brain infection","volume":"34","author":"Lebeaux","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2020.12.019","article-title":"How do I manage nocardiosis?","volume":"27","author":"Margalit","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e13509","DOI":"10.1111\/ctr.13509","article-title":"Nocardia infections in solid organ transplantation: Guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation","volume":"33","author":"Restrepo","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"ofaa090","DOI":"10.1093\/ofid\/ofaa090","article-title":"Safety and Outcomes of Linezolid Use for Nocardiosis","volume":"7","author":"Davidson","year":"2020","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/514340","article-title":"Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: A matched case-control study","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:29Z","timestamp":1760137529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":87,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["antibiotics11050612"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11050612","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]}}}